Alt Text
Office of Neuroscience Research > WUSTL Neuroscience News > NIH Weekly Funding Opportunities, Notices: May 11, 2018

NIH Weekly Funding Opportunities, Notices: May 11, 2018



 Notices

Requests for Applications

     

  • Investigation of the Transmission of Kaposi Sarcoma-associated Herpesvirus (KSHV)(R01 Clinical Trial Optional)
    (RFA-CA-18-013)
    National Cancer Institute
    Application Receipt Date(s): August 16, 2018), by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R21 Clinical Trial Not Allowed)
    (RFA-CA-18-014)
    National Cancer Institute
    Application Receipt Date(s): August 16, 2018, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Understanding Skeletal Effects of Type 1 Diabetes (R01 Clinical Trial Optional)
    (RFA-DK-18-002)
    National Institute of Diabetes and Digestive and Kidney Diseases
    Application Receipt Date(s): December 6, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Research Program Award (R35 Clinical Trial Optional)
    (RFA-NS-18-032)
    National Institute of Neurological Disorders and Stroke
    Application Receipt Date(s): July 13, 2018, by 5:00 PM local time of applicant organization. No late applications will be accepted for this Funding Opportunity Announcement. 
Program Announcements

     

  • Collaborative Activities to Expedite Environmental Health Science Research, Translation, and Community Engagement Across EHS Core Centers (Admin Supp - Clinical Trial Not Allowed)
    (PA-18-770)
    National Institute of Environmental Health Sciences
    Application Receipt Date(s): June 7, 2018, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • International Research Collaboration on Drug Abuse and Addiction Research (R01 Clinical Trial Optional)
    (PA-18-773)
    National Institute on Drug Abuse
    Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 Clinical Trial Optional)
    (PA-18-774)
    National Institute on Drug Abuse
    National Institute on Alcohol Abuse and Alcoholism
    Application Receipt Date(s): Standard dates apply , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34 Clinical Trial Optional)
    (PA-18-775)
    National Institute on Drug Abuse
    National Institute on Alcohol Abuse and Alcoholism
    Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Maternal Nutrition and Pre-pregnancy Obesity: Effects on Mothers, Infants and Children (R01 Clinical Trial Optional)
    (PA-18-776)
    National Institute of Nursing Research
    Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34 - Clinical Trial Optional)
    (PA-18-780)
    National Institute on Drug Abuse
    Application Receipt Date(s): Standard AIDS dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • NIOSH Occupational Safety and Health Research (R01)
    (PAR-18-769)
    National Institute for Occupational Safety and Health
    Application Receipt Date(s): July 6, 2018 for New applications; August 6, 2018 for Resubmission, Renewal, and Revision applications; Standard dates apply for future due dates. Electronically submitted applications must be submitted no later than 5:00 p.m., ET, on the listed application due date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Clinical Trial Required)
    (PAR-18-771)
    National Heart, Lung, and Blood Institute
    Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed)
    (PAR-18-772)
    National Heart, Lung, and Blood Institute
    Application Receipt Date(s): Standard dates apply , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Novel Genomic Technology Development (R01 Clinical Trial Not Allowed)
    (PAR-18-777)
    National Human Genome Research Institute
    Application Receipt Date(s): October 2, 2018; October 2, 2019; October 2, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Novel Genomic Technology Development (R21 Clinical Trial Not Allowed)
    (PAR-18-778)
    National Human Genome Research Institute
    Application Receipt Date(s): October 2, 2018; October 2, 2019; October 2, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Novel Genomic Technology Development (R43/R44 Clinical Trial Not Allowed)
    (PAR-18-779)
    National Human Genome Research Institute
    Application Receipt Date(s): October 2, 2018; October 2, 2019; October 2, 2020, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory Mechanisms (R21 Clinical Trials Not Allowed)
    (PAR-18-781)
    National Institute of Allergy and Infectious Diseases
    Application Receipt Date(s): September 4, 2018, September 3, 2019, and September 9, 2020 , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • NINDS Research Education Opportunities (R25 Clinical Trial Not Allowed)
    (PAR-18-782)
    National Institute of Neurological Disorders and Stroke
    Application Receipt Date(s): August 27, 2018, August 27, 2019, August 27, 2020), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.